Body Fluid Collection And Diagnostics Market Size, Share & Trends Analysis Report By Sample (Blood, Saliva, Urine, Cerebrospinal Fluid), By Product (Tests/Services, Instruments), By Technology, By Application, By Region, And Segment Forecasts, 2025 - 2030

Market Size & Trends

The global body fluid collection and diagnostics market size was estimated at USD 34.35 billion in 2024 and is projected to grow at a CAGR of 6.6% from 2025 to 2030. Rapid results, cost-effectiveness, and early prognosis of diseases are some of the factors contributing to the growth of the body fluid collection and diagnostics industry. Whereas the shift towards early detection and personalized medicine drives demand for body fluid diagnostics. Furthermore, innovations in in-vitro diagnostic techniques improve accuracy and efficiency, boosting its adoption. For instance, in May 2022, TECHKON GmbH announced the development of a novel method for body fluid analysis that could assess medical parameters and diagnose diseases simultaneously.

The COVID-19 outbreak has positively impacted the body fluid collection and diagnostics industry as it has boosted the demand for fluid diagnostic tests for the early detection of disease. Saliva, blood, urine, and semen are taken from the patients to examine viral RNA in the sample. Furthermore, several developments have been made globally, which have also contributed to the body fluid collection and diagnostics industry growth. For instance, in July 2021, Abbott announced launching the Panbio COVID-19 Antigen Self-Test in India to strengthen its rapid diagnostics product portfolio. It would support testing needs at work, at clinics, and at home.

Alzheimer's Disease (AD) is a severe neurodegenerative disease that requires the identification of precise biomarkers. The development and validation of early-stage biomarkers is a high research priority for existing diagnostics that can detect AD. Body-fluid biomarkers accurately reflect a synaptic failure in the brain and, as a result, could help improve diagnostic accuracy, track the course of the disease, and act as indicators for evaluating the effectiveness of early-onset disease-modifying therapies. In May 2022, the FDA authorized the marketing of a new test that could improve the diagnosis of AD. The Lumipulse test evaluates the ratio of -amyloid 1-40 and-amyloid 1-42 concentrations found in the human cerebral spinal fluid, which can help doctors in determining if a patient is expected to have amyloid plaques, a characteristic symptom of AD.

Body fluid samples contain a large number of naturally occurring biomarker proteins, which effectively show cancer progression. They are also utilized to find these biomarkers to validate the presence of cancer. For instance, in January 2022, scientists from the University of Illinois developed a tool that could detect cancer biomarkers in the body fluid samples. The quantification and detection of cancer-associated molecular biomarkers in such body fluids would help for minimally invasive cancer detection.

Furthermore, technological innovations in in-vitro diagnostics, such as high-throughput testing, automation, and integration of AI, have significantly enhanced diagnostic accuracy and efficiency. These advancements enable faster turnaround times and improved sensitivity, making body fluid diagnostic tools indispensable for modern healthcare. The availability of such innovative solutions supports the global adoption of these technologies.

Sample Insights

The blood sample segment held the largest revenue share at 47.8% in 2024. Body fluid traces recovered at crime scenes are important evidence for forensic researchers. They contain useful DNA evidence which can identify a victim or suspect. Crime scene investigation is one of the main fields in forensics. The introduction of advanced techniques such as single-nucleotide polymorphism (SNP) analysis, short tandem repeat (STR) recognition, mitochondrial deoxyribonucleic acid (DNA) analysis, and microfluid system for genetic material analysis extracted from the blood sample assists scientists in forensic investigations. In May 2022, BD expanded its partnership with Babson Diagnostics to advance diagnostic blood collection. The new care setting would allow patients to collect blood samples at home.

The urine segment is anticipated to exhibit considerable growth in the body fluid collection and diagnostics industry over the forecast period. Medical tests are becoming an important tool for the diagnosis and treatment of diseases. Urine collection is used for the metabolic evaluation of proteinuria, urinary stone disease, renal function estimation, and others. The testing is performed in an outpatient setting. In November 2022, researchers from the University of Tokyo stated that they are deriving new tests that could help in the early diagnosis of chronic kidney disease. Continuous developments in this field would further drive the segment’s growth.

Product Insights

The kits & consumables segment captured the largest revenue share of 67.4% in 2024. The segment is also expected to experience the fastest CAGR of 7.0% during the forecast period. The increasing demand for rapid and cost-effective kits coupled with easing government regulations for COVID-19 kits have contributed to the segment’s growth. For instance, in May 2021, COVID-19 home test kits received approval from the Indian Council of Medical Research, which issued detailed guidelines on how and who can use the kits. Mylab Discovery Solutions Ltd developed the CoviSelfTM COVID-19 OTC device whose process should be conducted according to the mobile app.

The tests/services are expected to exhibit a considerable CAGR of 6.3% over the forecast period. The rising adoption of advanced in-vitro technologies, such as high-sensitivity blood tests, urine analysis, and point-of-care solutions, has enhanced diagnostic accuracy and accessibility. This demand is further fueled by growing awareness and the global emphasis on preventive healthcare practices. Furthermore, specialized tests, such as cerebrospinal fluid analysis for neurological disorders and sweat tests for metabolic diseases, play pivotal roles in targeted diagnostics. In addition, point-of-care testing enhances accessibility, offering rapid and reliable solutions, thus driving the growth of this essential healthcare sector.

Application Insights

The diagnostics & monitoring segment captured the largest revenue share at 41.3% in 2024. Low cost, low invasiveness, and quick sample collection and processing are advantages of body fluid testing for disease diagnosis and monitoring. In addition, molecular expression level profiles in body fluid can aid in identifying changes to cellular networks and physiological conditions in diseased tissues. Body fluid analysis is now considered to be one of the most suitable techniques for the early diagnosis, monitoring, management, and evaluation of the early response to chronic diseases, as well as for identifying the possible pathogenesis of such abnormalities.

Therapeutic decision-making is expected to exhibit the fastest CAGR of 7.2% over the forecast period. Therapeutic decision-making is a pivotal driver of the body fluid collection and diagnostics industry as it underscores the need for precise and actionable diagnostic data to guide treatment strategies. By enabling early disease detection, monitoring of treatment efficacy, and personalized medicine approaches, diagnostic tools ensure optimized therapeutic outcomes. The increasing reliance on biomarkers and advanced testing technologies further highlights their role in minimizing trial-and-error treatment, reducing healthcare costs, and improving patient care.

Technology Insights

The Polymerase Chain Reaction (PCR) segment captured the largest revenue share of 58.8% in 2024. Body fluid DNA sequencing is a noninvasive technique for infectious diseases and genetic defects diagnosis. T Oligo-Primed Polymerase Chain Reaction is a robust technique that can be used for the minute DNA fragments amplification in body fluids. In August 2022, the Ministry of Health of the Democratic Republic of the Congo announced the recent Ebola Virus Disease outbreak. This has boosted the demand for RT-PCR in laboratories for virus detection. The sample is taken from oropharyngeal secretions.

The Next Generation Sequencing (NGS) is expected to exhibit the fastest CAGR of 7.3% over the forecast period. NGS has revolutionized every field of biological science. It has significantly reduced the sequencing costs. Several developments have been happening in this segment which is contributing to the segment’s growth. In September 2021, Selux Diagnostics, Inc. received FDA authorization for its NGS “phenotyping” platform for sterile body fluid samples and positive blood cultures. It is a single-platform solution for rapid antimicrobial susceptibility testing (AST) for specific sample types.

Regional Insights

North America body fluid collection and diagnostics market dominated and accounted for a 45.63% share in 2024. Factors such as the prevalence of chronic diseases like cancer and diabetes, along with a highly developed healthcare system, contribute significantly. The adoption of innovative technologies, such as liquid biopsies and molecular diagnostics, further accelerates growth in the region.

U.S. Body Fluid Collection And Diagnostics Market Trends

The U.S. body fluid collection and diagnostics market is projected to grow significantly during the forecast period, driven by the presence of key players, and their focus on launching cutting-edge diagnostic tools also boosts market expansion. The increasing incidence of lifestyle-related diseases and advancements in precision medicine play pivotal roles. Several developments, such as product launches and strategic initiatives between companies, have impacted the market positively. In May 2022, KDx Diagnostics Inc. entered into a partnership agreement with UroGPO to offer a non-invasive urine test, URO17, for bladder cancer in the U.S. Similarly, in July 2021, Psomagen Inc. expanded its COVID-19 diagnostic services to expand its product portfolio by adding at-home saliva collection kits.

Europe Body Fluid Collection And Diagnostics Market Trends

The Europe body fluid collection and diagnostics market is likely to emerge as a lucrative region in the industry, driven by technological advancements, strong collaboration between academic institutions and diagnostic companies, and favorable reimbursement policies. Regulatory frameworks in the EU support innovation while ensuring patient safety, making the region attractive for diagnostic developments.

The UK body fluid collection and diagnostics market is projected to grow during the forecast period. Increasing investments in advanced diagnostic facilities and public-private partnerships strengthen its growth trajectory. The rising prevalence of diseases requiring regular diagnostic monitoring also drives demand.

The France body fluid collection and diagnostics market is expected to show steady growth over the forecast period, driven by government initiatives to enhance diagnostic capabilities and the availability of state-of-the-art healthcare facilities. The focus on patient-centric healthcare and expanding molecular diagnostics further propels the market growth.

The body fluid collection and diagnostics market in Germany is projected to expand during the forecast period. Germany's established medical device industry and widespread adoption of in-vitro diagnostics position it as a growth leader in Europe. High investments in automation and integration of AI in diagnostic tools are additional factors contributing to market expansion.

Asia Pacific Body Fluid Collection And Diagnostics Market Trends

The Asia Pacific body fluid collection and diagnostics market is expected to experience the fastest CAGR of 7.6% during the forecast period, driven by increasing healthcare investments, improving infrastructure, and rising demand for affordable diagnostic solutions. High disease prevalence, coupled with growing awareness about early diagnostics, boosts market penetration. The increasing prevalence of diseases such as cancer, cardiovascular diseases, and other rare diseases has boosted the demand for body fluid diagnostics and collection. In November 2022, Roche Diagnostics announced launching its first automated cerebrospinal fluid (CSF)-based test in India for Alzheimer's disease.

The China body fluid collection and diagnostics market is projected to expand throughout the forecast period, driven by several key factors, including the rising prevalence of chronic diseases, and increased adoption of advanced diagnostics. The country is also investing heavily in research and development, further solidifying its position in the global market.

The Japan body fluid collection and diagnostics market is anticipated to grow during the forecast period, driven by a focus on innovation, an aging population requiring regular diagnostics, and government support for technological advancements in healthcare. Increased adoption of genetic testing and biomarker analysis.

Latin America Body Fluid Collection And Diagnostics Market Trends

The Latin America body fluid collection and diagnostics market is expected to experience significant growth throughout the forecast period. The market is growing steadily due to rising healthcare spending and increasing demand for advanced diagnostics. Efforts to address healthcare inequities and introduce cost-effective diagnostic solutions are fostering regional development.

The Brazil body fluid collection and diagnostics market is anticipated to grow during the forecast period. Brazil leads the Latin American market, supported by growing awareness about disease prevention, expanding diagnostic laboratories, and government efforts to improve access to healthcare in rural areas. Partnerships with international diagnostic companies further enhance growth prospects.

Middle East & Africa Body Fluid Collection And Diagnostics Market Trends

The Middle East & Africa body fluid collection and diagnostics market is anticipated to experience substantial growth during the forecast period. Saudi Arabia body fluid collection and diagnostics marketstands out in the MEA region with a focus on healthcare modernization, rapid adoption of innovative diagnostics, and regulatory frameworks encouraging technological advancements. The increasing prevalence of diseases such as diabetes and cancer further drives the need for effective diagnostic tools.

Key Body Fluid Collection And Diagnostics Company Insights

The global body fluid collection and diagnostics industry is highly competitive, with numerous players striving to maintain market leadership through innovation, product diversification, and strategic investments. These companies boast extensive product portfolios, a broad geographic presence, and robust distribution networks, allowing them to cater to a wide range of customer needs across both clinical and direct-to-consumer markets. To stay ahead of the competition, many industry leaders have made substantial investments in research and development, enabling them to introduce advanced and cutting-edge body fluid collection and diagnostics solutions. Key market players operating in this market are entering into several strategic collaborations and partnerships to expand their existing diagnostics and collection product portfolio. For instance, in August 2022, Mount Sinai entered into a partnership agreement with Exosome Diagnostics to accelerate research and development of real-time nucleic acid-based body-fluid diagnostics to promote personalized medicine.

Recent Developments

• In September 2024, Guardant Health and Policlinico Gemelli announced a partnership to create a dedicated in-house liquid biopsy testing service in Italy. This collaboration aims to enhance cancer detection and treatment through advanced diagnostic capabilities. The service will utilize Guardant Health's innovative technologies to provide patients with more accurate and timely results, ultimately improving patient care in the region.

• In July 2024, Guardant Health's Shield blood test received U.S. FDA approval as a primary colorectal cancer screening method, making it the first FDA-cleared blood test for this purpose. This milestone paves the way for Medicare reimbursement, broadening access to non-invasive cancer screening for eligible individuals. The approval supports Shield’s use in average-risk individuals aged 45 and older, ushering in a new era for colorectal cancer prevention and early detection.

• In March 2024, Spectrum Solutions introduced a new saliva-based diagnostic testing solution designed for faster and non-invasive health assessments. This innovation leverages saliva's potential for detecting a wide range of health conditions, offering convenience and reliability for patients and clinicians. The technology reflects a growing trend towards patient-friendly diagnostic methods in healthcare.

• In May 2023, Siemens Healthineers launched next-gen hematology analyzer products. The products include Atellica HEMA 580 and 570 analyzers. The analyzer provides intuitive interfaces & multi-analyzer automation connectivity to remove workflow roadblocks, supporting faster results.

Body Fluid Collection And Diagnostics Market Report Scope

Global Body Fluid Collection And Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global body fluid collection and diagnostics market report on the basis of sample, technology, application, product, and region:

• Sample Outlook (Revenue, USD Million, 2018 - 2030)

  • Blood

  • Saliva

  • Urine

  • Cerebrospinal Fluid

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Tests/Services

  • Kits & Consumables

  • Instruments

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • Next Generation Sequencing

  • Next Generation Sequencing (NGS)

  • Polymerase Chain Reaction (PCR)

  • Fluorescence in situ hybridization (FISH)

  • Others

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Diagnostics & Monitoring

  • Therapeutic Decision Making

  • Prognostics & Screening

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait